Dive Brief:
- Moon Surgical has added three people to its leadership team to support the commercialization of its surgical robot in the U.S. and Europe.
- The company on Tuesday said it hired Jonathan Conta, Jeff Semone and Jeff Driggs, as it prepares to expand the rollout of its Maestro soft tissue system from a limited launch that began a year ago.
- The robot has been used in more than 1,600 procedures worldwide, with 1,400 of those surgeries performed in the past year, Moon said.
Dive Insight:
Moon is scaling up quickly. After gaining Food and Drug Administration clearance for a noncommercial Maestro system in late 2022, it got the go-ahead to market the commercial version of the robot in June 2024.
Backed by investors that include Sofinnova Partners and the venture capital arms of Nvidia and Johnson & Johnson, Moon is one of a growing number of surgical robot developers moving in on market leader Intuitive Surgical’s turf.
Moon is now bringing in a trio of experienced medtech leaders as it enters the next phase of the robot’s release. Conta, Moon’s new chief marketing officer, spent more than 16 years at Intuitive overseeing marketing and product functions and leading commercial initiatives across both multiport and single-port platforms.
Semone, who was named chief quality and regulatory officer, previously led global quality and regulatory teams at Siemens Healthineers and Varian Medical Systems. Driggs, appointed president of U.S. sales, joins Moon from ConMed, where he led sales for the AirSeal platform. He previously held leadership positions at Intuitive.
„These additions come at a pivotal moment for Moon Surgical,” as the company wraps up its limited market release, Anne Osdoit, Moon CEO and partner at Sofinnova Partners, said in a statement.
„Their contributions position us to meet growing demand for Maestro and support our next stage of global expansion,“ said Osdoit.
Moon said its platform has supported procedures in 60 different types of minimally invasive surgeries, demonstrating its adaptability across specialties. The company, which has offices in Paris and San Francisco, also believes it can provide value in supporting high-volume outpatient care.
